The Potency Inflation Scandal: How Some Labs Are Juicing THC Numbers
In January 2026, a whistleblower at a mid-sized cannabis testing laboratory in Oregon sent a packet of documents to state regulators that confirmed what the industry had been whispering about for years. The lab, which this publication is not naming due to the ongoing investigation, had been systematically inflating THC potency results for its highest-volume clients — sometimes by as much as 5 to 8 percentage points.
The documents included internal emails from the lab’s director instructing analysts to “retest until viable” when results came in lower than a client’s expectations. They included spreadsheet comparisons showing the same flower samples tested at the whistleblower’s lab versus an independent lab, with consistent discrepancies in the inflated direction. And they included a frank assessment from one lab technician: “Everyone knows this is happening. We just cannot afford to be the honest lab that loses all its clients.”
This is the potency inflation scandal, and it is far from limited to one lab in Oregon.
The Economics of Inflated Numbers
To understand why THC inflation exists, you need to understand the market incentive structure. In most legal cannabis markets, THC percentage is the single most influential factor in wholesale pricing. Flower testing at 30 percent THC can sell for twice the wholesale price of genetically identical flower testing at 20 percent. Consumers have been trained — by marketing, by budtenders, by the number prominently displayed on every package — to equate higher THC with higher quality.
This creates an obvious problem. If Lab A consistently returns results of 22-25 percent THC for a cultivator’s flower, and Lab B returns 28-32 percent for the same product, which lab gets the business? In states where cultivators can choose their own testing lab — which is most of them — the answer is predictable.
“It is classic regulatory capture through market pressure,” says Dr. Kendra Williams, a chemist who spent six years working in cannabis testing before moving to an academic position at Portland State University. “The labs that are most honest are the ones that lose clients. The labs that are most generous with their numbers grow their business. There is no external force correcting this, because the regulators do not have the resources to routinely verify results.”
How Inflation Happens
The methods vary in sophistication and deniability. The most common techniques documented across multiple state investigations include:
Selective sample preparation. Cannabis flower is not uniform. The top of a bud, covered in trichomes, will test higher than the bottom. By selectively preparing samples from the most resinous portions of submitted material — rather than homogenizing the full sample as regulations require — a lab can push results upward by 2-4 percentage points without altering any data.
Moisture manipulation. THC potency is reported on a dry-weight basis. By allowing samples to dry further before testing, the ratio of THC to total weight increases. A sample with 5 percent higher moisture content will test approximately 5 percent lower in THC. Controlling the drying environment gives labs a subtle but effective lever.
Calibration drift. High-performance liquid chromatography (HPLC) instruments require regular calibration. Labs that “let their calibration drift” in the favorable direction can produce consistently inflated results while maintaining plausible deniability. If caught, they can point to calibration issues as an honest error.
Outright data manipulation. The most egregious cases, like the Oregon whistleblower’s lab, involve directly altering results in the laboratory information management system (LIMS). This is harder to detect than it should be, because many state regulatory frameworks do not require labs to maintain unalterable audit trails.
The Scale of the Problem
Quantifying potency inflation is inherently difficult — you are trying to measure a deception designed to be undetectable. But several data points paint a concerning picture.
A 2025 study by researchers at the University of Northern Colorado compared THC results from state-licensed labs against results from an independent reference lab using the same samples. Across 150 samples from five states, the licensed labs returned THC results that were, on average, 3.4 percentage points higher than the reference lab. Twenty percent of samples showed discrepancies greater than 5 percentage points.
State-level proficiency testing programs have repeatedly flagged similar issues. Michigan’s Marijuana Regulatory Agency reported in late 2025 that during its latest round of blind proficiency testing, 30 percent of licensed labs returned THC results outside the acceptable margin of error — all of them on the high side.
The statistical evidence is perhaps most damning. In several mature markets, the average reported THC potency of flower has risen steadily over the past five years, from roughly 20 percent to 28-30 percent. While breeding and cultivation improvements are real, the pace of this increase far outstrips what genetics and agronomy can explain. When independent researchers have tested retail products off the shelf, actual potency averages closer to 20-23 percent.
Consumer Harm
The immediate consumer harm is financial. If you are paying a premium for flower labeled at 32 percent THC and it actually tests at 24 percent, you are being defrauded. In a market where an eighth of “premium” flower can run $45-65, the potency premium can represent $10-20 of that price. Across the legal cannabis market, the aggregate consumer overpayment due to potency inflation likely reaches hundreds of millions of dollars annually.
But the harm extends beyond the wallet. Inflated THC numbers distort consumer decision-making. Medical patients dosing based on labeled potency may underdose. New consumers choosing products based on THC percentage are making decisions based on inaccurate information. And the broader consequence is an erosion of trust in the legal market’s core promise: that regulated cannabis is tested, labeled, and safe.
“The irony is devastating,” says consumer advocate Patricia Holm. “The entire justification for regulation over the black market is that consumers know what they are getting. If the lab results are fabricated, what exactly are we regulating?”
Regulatory Responses
Several states have begun addressing the problem, though progress is uneven.
California implemented a reference lab program in 2025, where the state’s Department of Cannabis Control maintains its own testing facility and randomly pulls samples from licensed labs for verification. Labs whose results consistently deviate from the reference lab face investigation. Two labs have had their licenses suspended since the program began.
Colorado now requires labs to participate in quarterly inter-laboratory comparison programs and publishes the results publicly. This naming-and-shaming approach has narrowed the gap between labs, though critics note it does not address whether the entire field is biased upward.
Michigan passed emergency rules in late 2025 requiring labs to maintain unalterable digital audit trails and submit to unannounced inspections. The rules also established a maximum acceptable deviation in proficiency testing, with automatic license review for labs that exceed it.
Oregon, prompted by the whistleblower case, is considering legislation that would create a state-run testing program where the state selects the testing lab rather than the cultivator. This “blind testing” model is considered the gold standard by most experts but faces fierce opposition from the existing lab industry, which argues it would create logistical nightmares.
Most other legal states have done little to address the issue, relying on self-policing within the lab industry — a strategy that has demonstrably failed.
What Needs to Change
The consensus among independent scientists, consumer advocates, and honest lab operators is that meaningful reform requires structural changes, not just stricter rules for the existing system.
Blind testing. Cultivators should not choose their own lab. When the entity being tested selects and pays the tester, the conflict of interest is inherent. Whether through a state-run assignment system or a randomized allocation process, removing this selection power is the single most impactful reform available.
Standardized methodology. Currently, different labs can use different extraction methods, sample preparation techniques, and instrument configurations, all within regulatory compliance. This makes comparison between labs genuinely difficult and provides cover for intentional inflation. Mandatory standardized methods would narrow the acceptable range of variation.
Reference standards. The cannabis testing industry still lacks the kind of certified reference materials that are standard in pharmaceutical and food testing. Federal prohibition has historically hampered the development of these standards, though the ongoing rescheduling process may open new avenues for NIST involvement.
Consumer education. Perhaps most fundamentally, the market needs to move away from THC percentage as the primary quality metric. Terpene profiles, growing practices, cure quality, and the entourage effect all contribute more to the consumer experience than raw THC numbers. Until consumers stop using THC as a proxy for quality, the economic incentive to inflate will persist.
The Path Forward
The potency inflation problem is not unique to cannabis. The history of food and pharmaceutical regulation is littered with analogous scandals — olive oil adulteration, pharmaceutical potency fraud, organic certification abuse. In each case, the pattern was the same: market incentives overwhelmed voluntary compliance, and only structural regulatory reform addressed the root cause.
Cannabis is at that inflection point now. The industry can either build a testing infrastructure that consumers can actually trust, or it can allow the current system to continue eroding the credibility that the legal market depends on. For an industry still fighting for legitimacy on the federal level, the stakes of that choice could not be higher.
The lab technician quoted at the beginning of this article put it most simply: “We are supposed to be the reason legal cannabis is better than street cannabis. If the numbers on the label are no more reliable than what your dealer told you, what is the point?”
That is a question the entire industry needs to answer. Soon.